Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 29, 2020 08:30 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with Topotecan

-- Novel approach leverages the ability of intracellular p53 protein to induce cell cycle arrest in healthy cells to prevent severe toxicities driven by chemotherapy’s off-target effects -- – In...
June 10, 2020 09:53 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares

WATERTOWN, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today the closing of its underwritten public offering of its common stock, including the exercise by...
June 04, 2020 09:15 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces Pricing of Public Offering of Common Stock

WATERTOWN, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a...
June 03, 2020 16:01 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces Proposed Public Offering of Common Stock

WATERTOWN, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today that it has commenced an underwritten public offering of shares of its common stock. Aileron...
June 01, 2020 07:00 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces Positive Interim Results from Phase 1b/2 Clinical Trial of ALRN-6924 for the Prevention of Topotecan-induced Toxicities During Treatment for Small Cell Lung Cancer

- - - Observed a protective effect against severe chemotherapy-induced anemia and thrombocytopenia across all dose levels - - - Management to host a conference call and webcast today at 8:30 a.m....
May 27, 2020 08:30 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent

WATERTOWN, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical...
May 11, 2020 08:30 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Enrollment completed in the dose optimization part of the ongoing Phase 1b/2 clinical trial of ALRN-6924 as a chemoprotection agent in cancer patients - - -Scheduled to report interim results from the...
April 22, 2020 08:30 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020

Presentation of interim results from the dose-optimization part of the Phase 1b myelopreservation study - - - Final data readout from Phase 1b for both dose optimization and schedule optimization in...
March 30, 2020 16:16 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

Phase 1b/2 clinical trial of ALRN-6924 as a myelopreservation agent for the protection against chemotherapy-induced toxicity in small cell lung cancer started dosing patients September 2019; interim...
December 18, 2019 08:30 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer

WATERTOWN, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the promotion...